Executive Summary CureDuchenne Ventures does not operate as a traditional venture capital firm. Instead, it represents a venture philanthropy model

Introduction Rome Therapeutics is a Boston-based biotechnology company on a mission to drug the "dark genome" – the vast

Introduction In recent months, several major biopharma companies have dramatically scaled back or outright halted their gene and cell therapy

Introduction Bristol Myers Squibb (BMS) and Takeda have recently joined forces with several peers in an ambitious data-sharing venture to

Executive Overview Pharmaceutical royalties occupy a complex regulatory landscape where classification depends fundamentally on structure rather than asset type. As

Complete Biotech Deals Report: September 29-October 5, 2025 Executive Summary The week of September 29-October 5, 2025, witnessed 19 distinct

Introduction: The Promise of Invisible Assets In the modern economy, the most valuable assets often cannot be seen or touched.

Investment Thesis and Business Strategy Ligand Pharmaceuticals operates a "royalty aggregation" business model, building a diversified portfolio of

Congratulations to Kumquat Biosciences on its brilliant naming -- the kumquat is indeed a great fruit, known for its sweet-tart

Executive Summary: CVR deployment reaches $35 billion across Q1-Q3 2025 transactions Contingent Value Rights (CVRs) have become integral to biotech